Clinical Cancer Research, Vol 4, Issue 5 1279-1285, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer

H Kumar, K Heer, PW Lee, GS Duthie, AW MacDonald, J Greenman, MJ Kerin and JR Monson
University of Hull Academic Surgical Unit, Castle Hill Hospital, Cottingham, United Kingdom.

Neovascularization has been shown to be essential for the growth of solid tumors. Vascular endothelial growth factor (VEGF) is one of the most important mediators of angiogenesis. This study was conducted to determine the significance of this cytokine as a tumor marker for staging colorectal cancer. Preoperative serum VEGF was measured in 108 colorectal cancer patients and in 136 normal healthy controls. The results of this study showed a significant difference between the four T classes, Union International Contre Cancer (UICC) stages, and Dukes' stages. In comparison to serum levels in controls (median, 173.8 pg/ml), VEGF levels were significantly elevated in T2 (P = 0.003), T3, and T4 (P < 0.0005); UICC I (P = 0.001), UICC II, UICC III, and UICC IV (P < 0.0005); and Dukes' A (P = 0.001), Dukes' B, and Dukes' C (P < 0.0005). Serum VEGF showed a significant elevation over control in node-negative (P < 0.0005) and in node-positive colorectal cancer (P < 0.0005) patients. Node-positive cancer had a significant elevation of serum VEGF compared to node-negative cancer (P = 0.008). This study reveals that preoperative serum VEGF can detect all but very early colorectal cancer i.e., T1 (P = 0.06).

This article has been cited by other articles:

				S. Hundt, U. Haug, and H. Brenner Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1935 - 1953. [Abstract] [Full Text] [PDF]

				R. D. Loberg, C. Ying, M. Craig, L. L. Day, E. Sargent, C. Neeley, K. Wojno, L. A. Snyder, L. Yan, and K. J. Pienta Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo Cancer Res., October 1, 2007; 67(19): 9417 - 9424. [Abstract] [Full Text] [PDF]

				Y.-W. Tien, K.-J. Chang, Y.-F. Chiu, K.-W. Huang, and P.-H. Lee Comparison of Angiogenic Factor Levels in Tumor Drainage and Peripheral Venous Blood From Colorectal Cancer Patients Ann. Surg. Oncol., November 1, 2006; 13(11): 1357 - 1363. [Abstract] [Full Text] [PDF]

				J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF]

				A. M. Jubb, H. I. Hurwitz, W. Bai, E. B. Holmgren, P. Tobin, A. S. Guerrero, F. Kabbinavar, S. N. Holden, W. F. Novotny, G. D. Frantz, et al. Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer J. Clin. Oncol., January 10, 2006; 24(2): 217 - 227. [Abstract] [Full Text] [PDF]

				M. Muta, G. Matsumoto, E. Nakashima, and M. Toi Mechanical Analysis of Tumor Growth Regression by the Cyclooxygenase-2 Inhibitor, DFU, in a Walker256 Rat Tumor Model: Importance of Monocyte Chemoattractant Protein-1 Modulation Clin. Cancer Res., January 1, 2006; 12(1): 264 - 272. [Abstract] [Full Text] [PDF]

				N. H. Fernando and H. I. Hurwitz Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 11 - 18. [Abstract] [Full Text] [PDF]

				Z. Zhou, R.-R. Zhou, H. Guan, C. D. Bucana, and E. S. Kleinerman E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model Mol. Cancer Ther., December 1, 2003; 2(12): 1313 - 1319. [Abstract] [Full Text] [PDF]

				K. Heer Reply Clin. Cancer Res., August 1, 2003; 9(9): 3515 - 3515. [Full Text] [PDF]

				R. T.-P. Poon, C. P.-Y. Lau, S.-T. Cheung, W.-C. Yu, and S.-T. Fan Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma Cancer Res., June 15, 2003; 63(12): 3121 - 3126. [Abstract] [Full Text] [PDF]

				B. C. Cooper, J. M. Ritchie, C. L. W. Broghammer, J. Coffin, J. I. Sorosky, R. E. Buller, M. J. C. Hendrix, and A. K. Sood Preoperative Serum Vascular Endothelial Growth Factor Levels: Significance in Ovarian Cancer Clin. Cancer Res., October 1, 2002; 8(10): 3193 - 3197. [Abstract] [Full Text] [PDF]

				A. Berglund, D. Molin, A. Larsson, R. Einarsson, and B. Glimelius Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma Ann. Onc., September 1, 2002; 13(9): 1430 - 1437. [Abstract] [Full Text] [PDF]

				H. J. M. Groen, E. G. E. de Vries, W. Wynendaele, W. T. A. van der Graaf, E. F. M. J. Lechuga, I. Poggesi, L. Y. Dirix, and A. T. van Oosterom PNU-145156E, a Novel Angiogenesis Inhibitor, in Patients with Solid Tumors: A Phase I and Pharmacokinetic Study Clin. Cancer Res., December 1, 2001; 7(12): 3928 - 3933. [Abstract] [Full Text] [PDF]

				K. Heer, H. Kumar, J. R. Read, J. N. Fox, J. R. T. Monson, and M. J. Kerin Serum Vascular Endothelial Growth Factor in Breast Cancer: Its Relation with Cancer Type and Estrogen Receptor Status Clin. Cancer Res., November 1, 2001; 7(11): 3491 - 3494. [Abstract] [Full Text] [PDF]

				R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]

				M. S. Gordon, K. Margolin, M. Talpaz, G. W. Sledge Jr, E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. C. Adelman Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer J. Clin. Oncol., February 1, 2001; 19(3): 843 - 850. [Abstract] [Full Text] [PDF]

				P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood, December 1, 2000; 96(12): 3712 - 3718. [Abstract] [Full Text] [PDF]

				M. L. George, S. A. Eccles, M. G. Tutton, A. M. Abulafi, and R. I. Swift Correlation of Plasma and Serum Vascular Endothelial Growth Factor Levels with Platelet Count in Colorectal Cancer: Clinical Evidence of Platelet Scavenging? Clin. Cancer Res., August 1, 2000; 6(8): 3147 - 3152. [Abstract] [Full Text]

				S. L. Starnes, B. W. Duncan, J. M. Kneebone, G. L. Rosenthal, T. K. Jones, R. G. Grifka, F. Cecchin, D. J. Owens, C. Fearneyhough, and F. M. Lupinetti VASCULAR ENDOTHELIAL GROWTH FACTOR AND BASIC FIBROBLAST GROWTH FACTOR IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASE J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 534 - 539. [Abstract] [Full Text] [PDF]

				Y. Kondo, S. Arii, A. Mori, M. Furutani, T. Chiba, and M. Imamura Enhancement of Angiogenesis, Tumor Growth, and Metastasis by Transfection of Vascular Endothelial Growth Factor into LoVo Human Colon Cancer Cell Line Clin. Cancer Res., February 1, 2000; 6(2): 622 - 630. [Abstract] [Full Text]

				P. Salven, L. Teerenhovi, and H. Joensuu A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma Blood, November 15, 1999; 94(10): 3334 - 3339. [Abstract] [Full Text] [PDF]

				L. Hefler, C. Tempfer, A. Obermair, K. Frischmuth, G. Sliutz, A. Reinthaller, S. Leodolter, and C. Kainz Serum Concentrations of Vascular Endothelial Growth Factor in Vulvar Cancer Clin. Cancer Res., October 1, 1999; 5(10): 2806 - 2809. [Abstract] [Full Text] [PDF]

				P. Salven, A. Orpana, and H. Joensuu Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor Clin. Cancer Res., March 1, 1999; 5(3): 487 - 491. [Abstract] [Full Text] [PDF]